Allogene Therapeutics Inc’s recently made public that its CHIEF FINANCIAL OFFICER Parker Geoffrey M. acquired Company’s shares for reported $683.0 on Jan 30 ’24. In the deal valued at $3.60 per share,190 shares were bought. As a result of this transaction, Parker Geoffrey M. now holds 819,590 shares worth roughly $3.45 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, MESSEMER DEBORAH M. sold 18,640 shares, generating $50,317 in total proceeds. Upon selling the shares at $2.70, the Director now owns 62,456 shares.
Before that, Mayo Stephen sold 10,000 shares. Allogene Therapeutics Inc shares valued at $42,855 were divested by the Director at a price of $4.29 per share. As a result of the transaction, Mayo Stephen now holds 25,328 shares, worth roughly $0.11 million.
JMP Securities downgraded its Allogene Therapeutics Inc [ALLO] rating to a Mkt perform from a a Mkt outperform in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Citigroup began covering ALLO with “Buy” recommendation on December 08, 2023. Citigroup started covering the stock on December 08, 2023. It rated ALLO as “a Buy”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -1.86% to $4.21. Over the last five days, the stock has lost -4.10%. Allogene Therapeutics Inc shares have risen nearly 31.15% since the year began. Nevertheless, the stocks have fallen -16.14% over the past one year. While a 52-week high of $6.89 was reached on 03/08/24, a 52-week low of $2.23 was recorded on 01/05/24. SMA at 50 days reached $4.33, while 200 days put it at $3.87. A total of 1.28 million shares were traded, compared to the trading of 1.51 million shares in the previous session.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 4.12, which if violated will result in even more drops to 4.03. On the upside, there is a resistance level at 4.39. A further resistance level may holdings at 4.56. The Relative Strength Index (RSI) on the 14-day chart is 41.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.56%. Stochastics %K at 8.06% indicates the stock is a buying.
How much short interest is there in Allogene Therapeutics Inc?
A steep rise in short interest was recorded in Allogene Therapeutics Inc stocks on Feb 29, 2024, growing by 1.92 million shares to a total of 25.01 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 23.09 million shares. There was a rise of 7.68%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 21.88% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.45.
